Intralesional (IL) injection of PV-10 has shown to induce regression of both injected and non-injected lesions in patients with melanoma. To determine an underlying immune mechanism, the murine B16 melanoma model and the MT-901 breast cancer model were utilized. In BALB/c mice bearing MT-901 breast cancer, injection of PV-10 led to regression of injected and untreated contralateral subcutaneous lesions. In a murine model of melanoma, B16 cells were injected into C57BL/6 mice to establish one subcutaneous tumor and multiple lung lesions. Treatment of the subcutaneous lesion with a single injection of IL PV-10 led to regression of the injected lesion as well as the distant B16 melanoma lung metastases. Anti-tumor immune responses were measured in splenocytes collected from mice treated with IL PBS or PV-10. Splenocytes isolated from tumor bearing mice treated with IL PV-10 demonstrated enhanced tumor-specific IFN-gamma production compared to splenocytes from PBS-treated mice in both models. In addition, a significant increase in lysis of B16 cells by T cells isolated after PV-10 treatment was observed. Transfer of T cells isolated from tumor-bearing mice treated with IL PV-10 led to tumor regression in mice bearing B16 melanoma. These studies establish that IL PV-10 therapy induces tumor-specific T cell-mediated immunity in multiple histologic subtypes and support the concept of combining IL PV10 with immunotherapy for advanced malignancies.
References
[1]
Triozzi PL, Khurram R, Aldrich WA, Walker MJ, Kim JA, et al. (2000) Intratumoral injection of dendritic cells derived in vitro in patients with metastatic cancer. Cancer 89: 2646–2654.
[2]
Guo J, Zhu J, Sheng X, Wang X, Qu L, et al. (2007) Intratumoral injection of dendritic cells in combination with local hyperthermia induces systemic antitumor effect in patients with advanced melanoma. Int J Cancer 120: 2418–2425.
[3]
Kidner TB, Morton DL, Lee DJ, Hoban M, Foshag LJ, et al. (2012) Combined intralesional Bacille Calmette-Guerin (BCG) and topical imiquimod for in-transit melanoma. J Immunother 35: 716–720.
[4]
Hofmann MA, Kors C, Audring H, Walden P, Sterry W, et al. (2008) Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma. J Immunother 31: 520–527.
[5]
Pilon-Thomas S, Li W, Briggs JJ, Djeu J, Mule JJ, et al. (2006) Immunostimulatory effects of CpG-ODN upon dendritic cell-based immunotherapy in a murine melanoma model. J Immunother 29: 381–387.
[6]
Boyd KU, Wehrli BM, Temple CL (2011) Intra-lesional interleukin-2 for the treatment of in-transit melanoma. J Surg Oncol 104: 711–717.
[7]
Kaufman HL, Kim DW, DeRaffele G, Mitcham J, Coffin RS, et al. (2010) Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol 17: 718–730.
[8]
Machado LM, Castro RS, Fontes BM (2009) Staining patterns in dry eye syndrome: rose bengal versus lissamine green. Cornea 28: 732–734.
[9]
Norn MS (1970) Rose bengal vital staining. Staining of cornea and conjunctiva by 10 prcent rose bengal, compared with 1 percent. Acta Ophthalmol (Copenh) 48: 546–559.
[10]
Thompson JF, Hersey P, Wachter E (2008) Chemoablation of metastatic melanoma using intralesional Rose Bengal. Melanoma Res 18: 405–411.
[11]
Mousavi H, Zhang X, Gillespie S, Wachter E, Hersey P (2006) Rose bengal induces dual modes of cell death in melanoma cells and has clinical activity against melanoma. Melanoma Res 2006.
[12]
Foote MC, Burmeister BH, Thomas J, Mark Smithers B (2010) A novel treatment for metastatic melanoma with intralesional rose bengal and radiotherapy: a case series. Melanoma Res 20: 48–51.
[13]
Pilon-Thomas S, Mackay A, Vohra N, Mule JJ (2010) Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma. J Immunol 184: 3442–3449.
[14]
Weide B, Derhovanessian E, Pflugfelder A, Eigentler TK, Radny P, et al. (2010) High response rate after intratumoral treatment with interleukin-2: results from a phase 2 study in 51 patients with metastasized melanoma. Cancer 116: 4139–4146.
[15]
Mastrangelo MJ, Sulit HL, Prehn LM, Bornstein RS, Yarbro JW, et al. (1976) Intralesional BCG in the treatment of metastatic malignant melanoma. Cancer 37: 684–692.
[16]
Rosenberg SA, Rapp HJ (1976) Intralesional immunotherapy of melanoma with BCG. Med Clin North Am 60: 419–430.
[17]
Sopkova B, Kolar V (1976) Intralesional BCG application in malignant melanoma. Neoplasma 23: 421–426.
[18]
Bornstein RS, Mastrangelo MJ, Sulit H, Chee D, Yarbro JW, et al. (1973) Immunotherapy of melanoma with intralesional BCG. Natl Cancer Inst Monogr 39: 213–220.
[19]
Morton DL, Eilber FR, Holmes EC, Hunt JS, Ketcham AS, et al. (1974) BCG immunotherapy of malignant melanoma: summary of a seven-year experience. Ann Surg 180: 635–643.
[20]
Harper JR (1982) Anaphylactic reaction to BCG vaccination. Lancet 1: 403–404.
[21]
Cohen MH, Elin RJ, Cohen BJ (1991) Hypotension and disseminated intravascular coagulation following intralesional bacillus Calmette-Guerin therapy for locally metastatic melanoma. Cancer Immunol Immunother 32: 315–324.
[22]
McKhann CF, Hendrickson CG, Spitler LE, Gunnarsson A, Banerjee D, et al. (1975) Immunotherapy of melanoma with BCG: two fatalities following intralesional injection. Cancer 35: 514–520.
[23]
Robinson JC (1977) Risks of BCG intralesional therapy: an experience with melanoma. J Surg Oncol 9: 587–593.
[24]
Felix EL, Jessup JM, Cohen MH (1978) Severe complications of intralesional BCG therapy in an unsensitized patient. Case report and clinical implications. Arch Surg 113: 893–896.
[25]
Portelance VQ, M.; Page (1976) Y (1976) Toxic effects of massive doses of BCG in mice, guinea pigs, and monkeys. Cancer Immunol Immunother 1: 63–67.
[26]
den Brok MH, Sutmuller RP, van der Voort R, Bennink EJ, Figdor CG, et al. (2004) In situ tumor ablation creates an antigen source for the generation of antitumor immunity. Cancer Res 64: 4024–4029.
[27]
Pilon-Thomas S, Kuhn L, Ellwanger S, Janssen W, Royster E, et al. (2012) Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma. J Immunother 35: 615–620.
[28]
Kodumudi KN, Weber A, Sarnaik AA, Pilon-Thomas S (2012) Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma. J Immunol 189: 5147–5154.
